Latanoprost

Generic Name: Latanoprost

Brand Names: Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₄₀O_₅

CAS Number: 130209-82-4

Unique Ingredient Identifier: 6Z5B6HVF6O

Background: Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...

Indication: Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...

Associated Conditions: Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)

Associated Therapies: -

Clinical Trials

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Phase 3

Not yet recruiting

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: DE-117B Eye Drops
Drug: Latanoprost

First Posted Date: 2024-10-31

Last Posted Date: 2024-11-04

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 338

Registration Number: NCT06666855

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

Phase 1

Recruiting

Conditions: Alopecia Areata

Interventions: Drug: Latanoprost

First Posted Date: 2024-02-02

Last Posted Date: 2024-04-16

Lead Sponsor: Egymedicalpedia

Target Recruit Count: 70

Registration Number: NCT06239324

Locations: 🇪🇬
Qena Hospital, Qinā, Egypt

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Phase 4

Recruiting

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Xalatan
Drug: Monoprost

First Posted Date: 2021-07-12

Last Posted Date: 2023-11-18

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 28

Registration Number: NCT04957329

Locations: 🇩🇰
Department of ophthalmology, rigshospitalet.glostrup, Glostrup, Danmark, Denmark
🇩🇰
Department of drug design and pharmacology, University of Copenhagen, Copenhagen, Denmark

Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

Phase 4

Active, not recruiting

Conditions: Non-segmental Vitiligo

Interventions: Radiation: NB-UVB
Drug: Latanoprost

First Posted Date: 2021-03-23

Last Posted Date: 2023-08-09

Lead Sponsor: Shaimaa Fawzy Abdel-rady Abdel-latif

Target Recruit Count: 150

Registration Number: NCT04811326

Locations: 🇪🇬
faculty of medicine, Aswan University, Aswan, Aswan Governorate, Egypt

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Monoprost
Drug: Xalatan

First Posted Date: 2021-02-08

Last Posted Date: 2021-02-08

Lead Sponsor: CHA University

Target Recruit Count: 57

Registration Number: NCT04743622

Locations: 🇰🇷
CHA University Bundang Medical Center, Seongnam, Bundang-gu, Korea, Republic of

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Not Applicable

Completed

Conditions: Glaucoma, Primary Open Angle

Interventions: Drug: Latanoprost
Drug: tafluprost

First Posted Date: 2021-02-04

Last Posted Date: 2021-02-04

Lead Sponsor: Santen Pharmaceutical (Taiwan) Co., LTD

Target Recruit Count: 1

Registration Number: NCT04737928

Locations: 🇨🇳
Chi Mei Hospital Liouying Branch, Tainan, Taiwan

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Phase 4

Conditions: Glaucoma; Drugs

Interventions: Device: CATS Tonometer
Drug: Latanoprost

First Posted Date: 2019-11-26

Last Posted Date: 2019-11-26

Lead Sponsor: Intuor Technologies, Inc.

Target Recruit Count: 72

Registration Number: NCT04178863

Locations: 🇺🇸
Arizona Eye Consultants, Tucson, Arizona, United States

Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

Phase 4

Conditions: Glaucoma

Interventions: Drug: Xalatan
Drug: Taflotan-S
Drug: Xalost S

First Posted Date: 2019-11-15

Last Posted Date: 2019-11-15

Lead Sponsor: Taejoon Pharmaceutical Co., Ltd.

Target Recruit Count: 144

Registration Number: NCT04164459

Locations: 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

Phase 4

Completed

Conditions: Glaucoma, Open-Angle

Interventions: Drug: Brimonidine Tartrate
Drug: Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops
Drug: Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension
Drug: Travoprost and Timolol
Drug: Bimatoprost and Timolol
Drug: Latanoprost

First Posted Date: 2019-05-29

Last Posted Date: 2019-05-29

Lead Sponsor: Afyon Kocatepe University Hospital

Target Recruit Count: 96

Registration Number: NCT03966560

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Phase 3

Conditions: Primary Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: CKD-351
Drug: Latanoprost
Drug: D930
Drug: Placebo of CKD-351
Drug: Placebo of D930

First Posted Date: 2018-12-03

Last Posted Date: 2018-12-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 384

Registration Number: NCT03762369

Locations: 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy